ADMA Biologics (NASDAQ:ADMA) Cut to Hold at Wall Street Zen
by Amy Steele · The Cerbat GemWall Street Zen cut shares of ADMA Biologics (NASDAQ:ADMA – Free Report) from a buy rating to a hold rating in a research note released on Saturday morning.
Several other analysts have also issued reports on ADMA. Mizuho decreased their price target on shares of ADMA Biologics from $30.00 to $24.00 and set an “outperform” rating on the stock in a research report on Monday, April 13th. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Zacks Research upgraded shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, ADMA Biologics has a consensus rating of “Buy” and a consensus target price of $25.67.
Check Out Our Latest Research Report on ADMA
ADMA Biologics Stock Performance
NASDAQ ADMA opened at $10.88 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. The firm has a market capitalization of $2.59 billion, a price-to-earnings ratio of 18.13 and a beta of 0.82. The company’s fifty day moving average is $13.34 and its two-hundred day moving average is $15.78. ADMA Biologics has a 52-week low of $7.21 and a 52-week high of $25.67.
ADMA Biologics (NASDAQ:ADMA – Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.20. The company had revenue of $139.16 million for the quarter, compared to analyst estimates of $139.80 million. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The business’s quarterly revenue was up 18.4% on a year-over-year basis. During the same period last year, the business posted $0.46 EPS. Equities research analysts forecast that ADMA Biologics will post 0.93 EPS for the current year.
Insider Transactions at ADMA Biologics
In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the firm’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the transaction, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at approximately $7,292,958. This trade represents a 2.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steve Elms acquired 7,000 shares of ADMA Biologics stock in a transaction dated Thursday, March 5th. The shares were acquired at an average cost of $15.67 per share, with a total value of $109,690.00. Following the completion of the acquisition, the director directly owned 2,038,730 shares in the company, valued at $31,946,899.10. This trade represents a 0.34% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 3.70% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On ADMA Biologics
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Lido Advisors LLC lifted its holdings in shares of ADMA Biologics by 3.8% during the 4th quarter. Lido Advisors LLC now owns 17,107 shares of the biotechnology company’s stock worth $312,000 after acquiring an additional 629 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in ADMA Biologics by 11.7% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 6,063 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 634 shares during the last quarter. Cim LLC lifted its holdings in ADMA Biologics by 0.7% during the 3rd quarter. Cim LLC now owns 91,486 shares of the biotechnology company’s stock valued at $1,341,000 after purchasing an additional 665 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in ADMA Biologics by 28.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 700 shares during the last quarter. Finally, Clearstead Advisors LLC lifted its holdings in ADMA Biologics by 55.7% during the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 795 shares during the last quarter. 75.68% of the stock is owned by institutional investors.
About ADMA Biologics
ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.
The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.